DLA Piper represented Switzerland-based Tecan Group AG (SIX: TECN), a global provider of laboratory instruments and solutions in biopharmaceuticals, forensics and clinical diagnostics, in a definitive agreement to acquire SPEware Corporation, based in Baldwin Park, California.

SPEware Corporation was founded in 1997 and provides advanced sample preparation solutions to the laboratory, by combining smart chemistry consumables with automation. SPEware Corporation was acquired for US$50 million cash, subject to working capital and other adjustments, and potential earn-out payments up to US$10 million cash. Following the transaction, SPEware Corporation will continue to be headquartered in California and its existing management team will continue to run day-to-day operations.

The DLA Piper team representing Tecan Group was led by partner Louis Lehot and included partners Shane Albright, Matt Oshinksy and Cisco Palao-Ricketts (Silicon Valley); Richard W. Ashley III (Chicago), Paolo Morante and Greg Ruback (New York); of counsel Cathryn Le Regulski (Northern Virginia); and associates Eric Chow, Philipp Tsukanov, SeoJung Park, Karl Kobylecki (Silicon Valley), and Cherelle Glimp (New York).

DLA Piper's global life sciences lawyers work across practice areas and offices to support biotechnology and medical device clients at every stage of growth, from startups to fast-growing and mid-market businesses to mature global enterprises. Last year, according to mergermarket’s league tables for legal advisors, DLA Piper again earned the No. 1 ranking globally for overall deal volume.